Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964825 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL3459376 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL964362 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL12946842 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL10327145 | 0.90 | KDM4E (0.43) | SMN1; SMN2KMT2ALMNAMEN1KDM4E | |
| SCHEMBL3460501 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL12946922 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL10180845 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL3459084 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2ALMNAPKMHPGD | |
| SCHEMBL12946908 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2ALMNAPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | SMN1; SMN2 2850/4885KMT2A 3420/4885LMNA 3817/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | SMN1; SMN2 2850/4885KMT2A 3420/4885LMNA 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.